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Abstract: Chromophobe renal cell carcinoma (chRCC) is a renal tumor subtype with a good
prognosis, characterized by multiple chromosomal copy number variations (CNV). The World Health
Organization (WHO) chRCC classification guidelines define a classic and an eosinophilic variant.
Large cells with reticular cytoplasm and prominent cell membranes (pale cells) are characteristic
for classic chRCC. Classic and eosinophilic variants were defined in 42 Swiss chRCCs, 119 Japanese
chRCCs and in whole-slide digital images of 66 chRCCs from the Cancer Genome Atlas (TCGA)
kidney chromophobe (KICH) dataset. 32 of 42 (76.2%) Swiss chRCCs, 90 of 119 (75.6%) Japanese
chRCCs and 53 of 66 (80.3%) TCGA-KICH were classic chRCCs. There was no survival difference
between eosinophilic and classic chRCC in all three cohorts. To identify a genotype/phenotype
correlation, we performed a genome-wide CNV analysis using Affymetrix OncoScan® CNV Assay
(Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA) in 33 Swiss chRCCs. TCGA-KICH subtypes
were compared with TCGA CNV data. In the combined Swiss and TCGA-KICH cohorts, losses of
chromosome 1, 2, 6, 10, 13, and 17 were significantly more frequent in classic chRCC (p < 0.05, each),
suggesting that classic chRCC are characterized by higher chromosomal instability. This molecular
difference justifies the definition of two chRCC variants. Absence of pale cells could be used as main
histological criterion to define the eosinophilic variant of chRCC.
Keywords: chromophobe renal cell carcinoma; pale cell; eosinophilic variant; chromosomal loss;
copy number analysis; renal cell carcinoma
1. Introduction
Chromophobe renal cell carcinoma (chRCC) is a distinct histological entity of renal cell carcinoma
(RCC) described by Thoenes et al. [1] in 1985. chRCC accounts for approximately 5–7% of RCC [2–4].
Thoenes et al. used the term chromophobe cell for larger cells with reticular, but not clear cytoplasm and
prominent cell membranes (plant cell-like) [1,2]. Three years later, these authors described eosinophilic
cells with smaller size and with fine oxiphilic granularity as a second cell component of chRCC [3].
Crotty et al. used the term pale cell instead of the formerly used term chromophobe cell and considered
pale cell and eosinophilic cell [5] as two main cell types in chRCC. Several ultrastructural studies
showed that pale cells are characterized by numerous cytoplasmic microvesicles, a feature probably
related to defective mitochondrial development, whereas mitochondria are abundant in eosinophilic
cells [2,6–8].
Most chRCCs consist of both cell types, which are typically mixed, with eosinophilic cells usually
arranged at the center and pale cells usually arranged at the periphery of the sheets or nests [2].
The 2016 World Health Organization (WHO) renal tumor classification acknowledges an eosinophilic
variant of chRCC “that is sometimes difficult to distinguish from renal oncocytoma” [3–5,9,10] but
there are no exact diagnostic criteria to classify an eosinophilic chRCC.
Previous studies have demonstrated losses of one copy in many chromosomes, especially in
chromosomes 1, 2, 6, 10, 13, 17, 21 and sex chromosome in the majority of chRCCs (~71%). Losses of
chromosome 1 and sex chromosome have been also reported in oncocytoma [4,9,11–15]. Recently,
mutation of TP53, PTEN, HNF1B were observed in chRCCs [13,16,17]. Previous studies also disclosed
frequent somatic mitochondrial DNA mutations in oncocytoma [13,18,19] and chRCCs [9,20], but a
clear genotype/phenotype correlation has never been described in chRCC.
In this study, we analyzed the histopathological variants of chRCCs in 42 Swiss, 119 Japanese
and in whole-slide digital images of 66 chRCCs from The Cancer Genome Atlas (TCGA) Kidney
Chromophobe (KICH) dataset. Further, we utilized single-nucleotide polymorphism (SNP) arrays to
assess genome-wide copy number variation (CNV) and correlated CNV to the histological variants in
the Swiss and the TCGA-KICH data [13].
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2. Results
2.1. Swiss Cohort
There were 22 of 33 (66.7%) classic chRCCs with typical voluminous pale cells in the Swiss cohort
(Table 1). Tumors with and without pale cell are shown in Figure 1. There was no association between
the chRCC subtypes with age, sex, and pT stage (Table 2). Molecular analysis using the OncoScan®
CNV Assay (Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA) revealed loss of part (>5% of
gene loci) or the entirety of chromosome 1, 2, 6, 10, 13, 17, 21, and sex chromosome in the majority
of cases (Figure 2 and Table 2). Among these chromosomal losses, chromosome 1 was most affected
(32/33, 97.0%). Chromosome 2 (24/33, 72.7%), 6 (26/33, 78.8%), 10 (21/33, 63.6%), 13 (23/33, 69.7%),
17 (25/33, 75.8%), and 21 (17/33, 51.5%) were less frequently altered (Table 2).
Table 1. Demographic and clinical characteristics.
Characteristics Swiss Cohort (Total) TCGA-KICH Japanese Cohort
Patient number 42 66 119
Age (years)
Range 18–87 17–86 26–88
Median 59 50 60
Gender
Female 13 (31.0%) 27 (40.9%) 69 (58.0%)
Male 29 (69.0%) 39 (59.1%) 50 (42.0%)
pT Stage or T stage, n (%) *
1 25 (59.5%) 21 (31.8%) 85 (71.4%)
2 11 (26.2%) 25 (37.9%) 19 (16.0%)
3 6 (14.3%) 18 (27.3%) 14 (11.8%)
4 0 (0%) 2 (3.0%) 1 (0.8%)
Subtype
classic 32 (76.2%) 53 (80.3%) 90 (75.6%)
eosinophilic 10 (23.8%) 13 (19.7%) 29 (24.4%)
* Swiss and Japanese cohort: pT stage, TCGA-KICH: T stage.
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Table 2. Copy number variation (chromosomal losses) in classic and eosinophilic chromophobe renal cell carcinomas (chRCCs) (Chr. = chromosome) from 33 Swiss
chRCCs (Affymetrix OncoScan® CNV Assay; Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA) and combined Swiss/TCGA-KICH cohorts (The Cancer
Genome Atlas copy number variation data).
Cohort Swiss Combined *
Characteristics n (%) Classic chRCCa (%)
Eosinophilic
chRCC b (%) p-Value n (%)
Classic chRCC
a (%)
Eosinophilic
chRCC b (%) p-Value
Total 33 22 (66.7) 11 (33.3) 99 75 (75.8) 24 (24.2)
Chr.1 status
Loss 32 (97.0) 22 (100) 10 (90.9) n.s. 87 (87.9) 70 (93.3) 17 (70.8) <0.01
No loss 1 (3.0) 0 (0) 1 (9.1) 12 (12.1) 5 (6.7) 7 (29.2)
Chr.2 status
Loss 24 (72.7) 19 (86.4) 5 (45.5) <0.05 73 (73.7) 63 (84.0) 10 (41.7) <0.001
No loss 9 (27.3) 3 (13.6) 6 (54.5) 26 (26.3) 12 (16.0) 14 (58.3)
Chr.6 status
Loss 26 (78.8) 21 (95.5) 5 (45.5) <0.01 78 (78.8) 68 (90.7) 10 (41.7) <0.001
No loss 7 (21.2) 1 (4.5) 6 (54.5) 21 (21.2) 7 (9.3) 14 (58.3)
Chr. 10 status
Loss 21 (63.6) 16 (72.7) 5 (45.5) n.s. 70 (70.7) 62 (82.7) 8 (33.3) <0.001
No loss 12 (36.4) 6 (27.3) 6 (54.5) 29 (29.3) 13 (17.3) 16 (66.7)
Chr.13 status
Loss 23 (69.7) 17 (77.3) 6 (54.5) n.s. 68 (68.7) 57 (76.0) 11 (45.8) 0.01
No loss 10 (30.3) 5 (22.7) 5 (45.5) 31 (31.3) 18 (24.0) 13 (54.2)
Chr.17 status
Loss 25 (75.8) 19 (86.4) 6 (54.5) n.s. 75 (75.8) 64 (85.3) 11 (45.8) <0.001
No loss 8 (24.2) 3 (13.6) 5 (45.5) 24 (24.2) 11 (14.7) 13 (54.2)
Chr.21 status
Loss 17 (51.5) 12 (54.5) 5 (45.5) n.s. 52 (52.5) 42 (56.0) 10 (41.7) n.s.
No loss 16 (48.5) 10 (45.5) 6 (54.5) 47 (47.5) 33 (44.0) 14 (58.3)
Loss of any chromosome c
present 29 (87.9) 21 (95.5) 8 (72.7) n.s. 83 (83.8) 69 (92.0) 14 (58.3) <0.001
absent 4 (12.1) 1 (4.5) 3 (27.3) 16 (16.2) 6 (8.0) 10 (41.7)
a defined as the presence of pale cells, b defined as absence of pale cells, c: Loss of any: Loss of any chromosome among chr. 2, 6, 10, 13, 17, or 21, n.s.: not significant, * combined
Swiss/TCGA-KICH cohorts.
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Figure 2. Copy number (CN) alterations and copy-neutral loss-of-heterozygosity detected by Affymetrix
OncoScan® CNV Assay of 22 classic chromophobe renal cell carcinomas (chRCCs) (upper panel) and 11
eosinophilic chRCCs (lower panel) in the Swiss cohort. Red signal, blue signal, and yellow signal show
copy-number loss, copy-number gain, and copy-neutral loss-of-heterozygosity, respectively. Loss of
any: Loss of any chromosome among chromosome 2, 6, 10, 13, 17, or 21. Red: Present, Blue: Absent.
The Correlation between chromosomal losses and clinicopathological features of 33 chRCCs
are summarized in Table 2. Classic chRCC showed significantly more chromosome 2 (p < 0.05),
and chromosome 6 losses (p < 0.01) than eosinophilic RCC (Table 2). Among 22 classic chRCCs with
pale cells, 19/22 (86.4%) showed chromosome 2 loss, 21/22 (95.5%) chromosome 6 loss, 16/22 (72.7%)
chromosome 10 loss, 17/22 (77.3%) chromosome 13 loss, and 19/22 (86.4%) chromosome 17 loss.
2.2. TCGA Cohort
53 of 64 (80.3%) were classic chRCCs (Tables 1 and 2). Classic chRCCs from the Cancer Digital
Slide Archive are shown in Figure 3. The publicly available copy number variation (CNV) analysis
data of TCGA-KICH dataset revealed losses of chromosomes 1, 2, 6, 10, 13, 17, and 21 in the majority of
chRCC as previously reported [13]. The CNV data are summarized in Table S1.
Classic chRCC showed significantly more chromosome 1, 2, 6, 10, 17 copy number (CN) losses
(p < 0.01) and chromosome 13 CN loss (p < 0.05) (Table S1). When the Swiss and TCGA-KICH cohorts
were combined, losses of chromosome 1, 2, 6, 10, 13 and 17 were significantly more frequent in classic
chRCC with pale cells (p < 0.05, each) (Table 2).
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Figure 3. Representative microscopic images of chromophobe renal cell carcinomas (chRCCs) in the
Cancer e o e Atlas Kidney Chromophobe (TCGA-KICH) cohort, whole-slide images from the Cancer
Digital Slide Archive [21] (a) classic chRCC with pale cells (TCGA-KL-8345). (b) eosinophilic chRCC
without pale cells (TCGA-KL-8326).
2.3. Chromophobe Renal Cancer Subtype and Survival
Higher pT stage (pT3–4 vs. pT1–2) and higher pN stage (pN1–2 vs. pN0) were significantly
associated with worse survival by log-rank test (Figure 4a,b) and univariate Cox regression analysis
(Table 3) in the Swiss-TCGA-Japanese cohort. There was no overall survival (OS) difference between
classic and eosinophilic chRCC subtypes in the three independent cohorts of the Swiss (42 cases),
TCGA-KICH (64 cases) and the Japanese (119 cases) nor in the Swiss-TCGA-Japanese combined cohort
(Figure 4c). Multivariate Cox regression analysis, including pT stage (pT3–4 vs. pT1–2), pN stage
(pN1–2 vs. pN0), WHO/ISUP grade (G de 3/4 vs. Grade 2), and chRCC subtype show d that pT stage
and pN stage were independent prognostic factors for OS, where s no prognostic impact of the chRCC
subtype or WHO/International Society of Urological Pathology (ISUP) grade was observed (Tabl 3).
Cancers 2019, 11, 1492 6 of 14 
 
(a) (b) 
Figure 3. Representative microscopic images of chromophobe renal cell carcinomas (chRCCs) in the 
Cancer Genome Atlas Kidney Chromophobe (TCGA-KICH) cohort, whole-slide images from the 
Cancer Digital Slide Archive [21] (a) classic chRCC with pale cells (TCGA-KL-8345). (b) eosinophilic 
chRCC without pale cells (TCGA-KL-8326). 
Classic chRCC showed significantly more chromosome 1, 2, 6, 10, 17 copy number (CN) losses 
(p < 0.01) and chromosome 13 CN loss (p < 0.05) (Table S1). When the Swiss and TCGA-KICH cohorts 
were combined, losses of chromosome 1, 2, 6, 10, 13 and 17 were significantly more frequent in classic 
chRCC with pale cells (p < 0.05, each) (Table 2). 
2.3. Chromophobe Renal Cancer Subtype and Survival  
Higher pT stage (pT3–4 vs pT1–2) and higher pN stage (pN1–2 vs pN0) were significantly 
associated with worse survival by log-rank test (Figure 4a,b) and univariate Cox regr ssion analysis 
(Table 3) i  the Swiss-TCGA-Japanese cohort. There was no overall survival (OS) difference between 
classic and eosin philic RCC ubtypes in the three independent cohorts of the Swiss (42 ses), 
TCGA-KICH (64 cases) and th  Japanese (119 cases) nor in the Swiss-TCGA-Japanese combined 
cohort (Figure 4c). Multivariate Cox regression analysis, including pT stage (pT3–4 vs pT1–2), pN 
stage (pN1–2 vs pN0), WHO/ISUP gr de (Grade 3/4 vs Grade 2), and chRCC subtype showed that 
pT stage and pN stage were independent prognostic factors for OS, whereas no prognostic impact of 
the chRCC subtype or WHO/International Society of Urological Pathology (ISUP) grade was 
observed (Table 3). 
 
(a) 
 
(b) 
 
(c) 
Figure 4. Overall survival stratified by (a) pT Stage or T stage (1–2 versus 3–4), (b) pN stage or N stage
(pN1–2 versus pN0), and (c) chromophobe renal cell carcinoma (chRCC) subtype in all 225 chRCC
patients combined from the Swiss, the Cancer Genome Atlas Kidney Chromophobe (TCGA-KICH),
and Japanese cohorts. pT Stage or T stage: Swiss and Japanese cohorts, pT stage, and TCGA-KICH, T
stage was used for the calculation. pN stage or N stage: Swiss and Japanese cohorts, pN stage, and
TCGA-KICH, N stage was used for the calculation.
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Table 3. Univariate and Multivariate Cox regression analysis on overall survival of 225 chRCC patients
combined from Swiss, TCGA-KICH and Japanese cohorts.
Variables
Univariate Multivariate
HR (95%CI) p-Value HR (95%CI) p-Value
pT Stage or T stage * (3–4 vs. 1–2) 4.809 (2.275–10.16) <0.001 3.177 (1.336–7.556) <0.01
pN Stage or N stage * (1–2 vs. 0) 42.95 (13.16–140.1) <0.001 21.140 (5.612–79.650) <0.001
WHO/ISUP grade (Grade 3/4 vs. Grade 2) ** 1.667 (0.502–5.537) n.s. 2.010 (0.594–6.804) n.s.
Subtype (classic vs. eosinophilic) 0.756 (0.321–1.782) n.s. 0.520 (0.207–1.303) n.s.
HR, hazard ratio, CI, confidence interval, n.s.: not significant. * Swiss and Japanese cohort: pT/pN stage, TCGA-KICH:
T/N stage. ** WHO/ISUP grading system is not recommended for chRCC.
2.4. Chromosomal Copy Number Variation and Survival
Both, CN data and survival data were available from 30 Swiss chRCCs and 64 chRCCs from
TCGA-KICH cohort. In the Swiss cohort, neither CN losses of each chromosome 1, 2, 6, 10, 13, 17,
21 in single analysis nor CN loss of any chromosome among chromosome 1, 2, 6, 10, 13, 17, 21 were
associated with worse survival by log-rank test and univariate Cox regression analysis (Table 4).
In the combined Swiss-TCGA cohort, only chromosome 21 CN loss was associated with shorter
overall survival, whereas all other chromosomes were not associated with survival (Figure 5a and
Table 4). Multivariate analysis showed that pT stage was the only independent prognostic factor for
OS whereas no association was found between OS and CN loss of chromosome 21 or CN loss of any
other chromosome among chromosome 1, 2, 6, 10, 13, 17, 21 (Table 5). Importantly, chRCCs without
any CN loss of chromosome 1, 2, 6, 10, 13, 17, 21 groups revealed 100% survival in the combined
Swiss/TCGA-KICH cohorts (Figure 5b and Table 4).
Table 4. Univariate survival analysis (Kaplan-Meier) with log-rank test (overall survival) of 94 chRCC
patients combined from Swiss and TCGA-KICH cohorts (Chr. = chromosome).
Cohort Swiss Combined
Characteristics Cases, n (%) PatientDeath, n (%) p-Value Cases, n (%)
Patient
Death, n (%) p-Value
Total 30 5 (16.7) 94 14 (14.9)
Chr.1 status
Loss 30 (100) 5 (100) n.s. 83 (88.3) 14 (100) n.s.
No loss 0 (0) 0 (0) 11 (11.7) 0 (0)
Chr.2 status
Loss 22 (73.3) 4 (80.0) n.s. 69 (73.4) 12 (85.7) n.s.
No loss 8 (26.7) 1 (20.0) 25 (26.6) 2 (14.3)
Chr.6 status
Loss 25 (83.3) 4 (80.0) n.s. 75 (79.8) 12 (85.7) n.s.
No loss 5 (16.7) 1 (20.0) 19 (20.2) 2 (14.3)
Chr. 10 status
Loss 19 (63.3) 3 (60.0) n.s. 67 (71.3) 12 (85.7) n.s.
No loss 11 (36.7) 2 (40.0) 27 (28.7) 2 (14.3)
Chr.13 status
Loss 21 (70.0) 4 (80.0) n.s. 64 (68.1) 11 (78.6) n.s.
No loss 9 (30.0) 1 (20.0) 30 (31.9) 3 (21.4)
Chr.17 status
Loss 23 (76.7) 4 (80.0) n.s. 71 (75.5) 11 (78.6) n.s.
No loss 7 (23.3) 1 (20.0) 23 (24.5) 3 (21.4)
Chr.21 status
Loss 17 (56.7) 4 (80.0) n.s. 50 (53.2) 12 (85.7) <0.05
No loss 13 (43.3) 1 (20.0) 44 (46.8) 2 (14.3)
Loss of any chromosome *
present 30 (100) 5 (100) n.s. 83 (88.3) 14 (100) n.s.
absent 0 (0) 0 (0) 11 (11.7) 0 (0)
* Loss of any chromosome: Loss of any chromosome among chr. 1, 2, 6, 10, 13, 17 or 21, n.s.: not significant.
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Figure 5. Overall survival stratified by (a) chromosome 21 status (Chr.21 loss versus No chr.21 loss)
and (b) Loss of any chromosome among chromosome 1, 2, 6, 10, 13, 17, or 21 (Loss versus No loss)
in 94 chRCC patients combined from Swiss and the Cancer Genome Atlas Kidney Chromophobe
(TCGA-KICH) cohorts.
Table 5. Univariate and Multivariate Cox regression analysis (overall survival) of 94 chRCC patients
combined from Swiss and TCGA-KICH cohorts.
Variables
Univariate Multivariate Multivariate
HR (95%CI) p-Value HR (95%CI) p-Value HR (95%CI) p-Value
pT Stage or T stage a
(3–4 vs. 1–2)
6.323
(2.078–19.25) 0.001
5.505
(1.935–17.450) <0.01
6.344
(2.010–20.03) <0.01
Loss of any chromosome b,c
(present vs. absent)
2.503
(0.331–320.637) n.s.
1.319
(0.154–172.711) n.s.
Loss of chromosome 21
(present vs. absent)
4.684
(1.047–20.95) <0.05
4.480
(1.000–20.08) n.s.
HR, hazard ratio, CI, confidence interval, n.s.: not significant. a: Swiss and Japanese cohort: pT stage, a Swiss and
Japanese cohort: pT stage, TCGA-KICH: T stage, b Loss of any: Loss of any chromosome of chromosome 1, 2, 6,
10, 13, 17, or 21, c Firth correction was used because of quasi-complete separation, there was no event in one of
the subgroups.
3. Discussion
In our study, we used the absence of voluminous pale cells to define eosinophilic chRCC. Using this
definition, classic chRCC is associated with significantly more frequent losses of chromosomes 1, 2, 6,
10, 13, and 17.
Various cytogenetic, comparative genomic hybridization, and recent molecular studies have
confirmed the very unique and characteristic genotype with multiple chromosomal losses in
chRCC [4,9,11–15]. However, previous attempts to correlate histological variants of chRCCs with a
specific genotype have failed. More than 10 years ago, Brunelli et al. analyzed classic and eosinophilic
chRCCs by fluorescence in situ hybridization, but they have not observed different frequencies of
chromosomal 2, 6, 10, and 17 losses [11]. This is in contrast to our OncoScan results with more
chromosomal CNV in classic than in eosinophilic chRCC. Our results are in line with a TCGA-KICH
study by Davis et al., demonstrating in almost all classic chRCC there are characteristic chromosomal
copy-number losses, whilst approximately 50% of all eosinophilic chRCC (9 of 19) experienced no
chromosomal copy-number alterations [13]. Recently, Trpkov et al. proposed low-grade oncocytic
tumors (LOT) as an emerging renal tumor entity [22]. They argue that LOT lacks multiple chromosomal
losses and gains, and exhibits indolent clinical behavior. This tumor does not fit completely into
either oncocytoma or eosinophilic chRCC, despite showing some similarities with both entities.
Further studies are warranted to proof that LOT potentially represents a distinct type of tumor or if
they should be regarded as variant of eosinophilic chRCC.
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During our study design and the re-evaluation of histological slides for this study, we realized
that there are no stringent diagnostic criteria to classify eosinophilic chRCC. The current 2016 WHO
classification states that eosinophilic chRCC is almost purely composed of eosinophilic cells and that
the majority of cells should be eosinophilic cells [2]. Given this lack of exact criteria, we decided to use
the complete absence of pale cells as definition for eosinophilic chRCC, because pale cells are easily
identifiable and can be clearly separated from eosinophilic cells.
As a consequence of this lack of stringent criteria for subtyping chRCC, distribution of chRCC
variants varies extremely between different studies [2,3,10,11,23,24]. Davis et al. recently classified the
TCGA-KICH tumors as classic and eosinophilic variants [13]. Our evaluation of TCGA-KICH digital
whole slide images for chRCC only partially matched his classification of classical and eosinophilic
variants, which can be explained by our more conservative cut-off to define eosinophilic chRCC
(complete absence of pale cells).
Interestingly, there were no survival differences between eosinophilic and classic chRCC in 3
cohorts from TCGA, Japan and Europe. Given the morphological overlap between eosinophilic chRCC
and benign oncocytoma, one could assume that eosinophilic chRCC have a better prognosis than
classic chRCC. The prognostic similarity between eosinophilic and classic chRCC further underlines
the importance to clearly separate eosinophilic chRCC from oncocytoma. Most importantly, classic
chRCC had significantly more losses of chromosome 2 and 6 in the Swiss tumors and more losses of
chromosome 1, 2, 6, 10, 13, and 17 in the TCGA dataset. Swiss classic chRCC showed only a trend
to more chromosome 1, 10, 13, or 17 losses, probably due to the lower number of cases (Table 2).
Almost all eosinophilic and all classic chRCC (91–100%) revealed chromosome 1 loss, suggesting that
chromosome 1 loss may be an early event in chRCC tumorigenesis. Chromosome 1 losses have even
been identified in oncocytoma [9,11,12,15]. This could be due to the misclassification of eosinophilic
chRCCs as oncocytoma, but it is also tempting to speculate that there is a stepwise progression from
oncocytoma to eosinophilic or classic chRCC with chromosome 1 loss as a genetic driver.
Treatment outcomes are poorly characterized in patients with metastatic chRCC. This is a
consequence of rare metastasis of this subtype. Patients with metastatic chRCC can be treated
with tyrosine kinase inhibitors. It has been recently shown that outcomes between metastatic
chRCC and clear cell renal cell carcinoma (ccRCC) are similar when treated with conventional
targeted therapies [25]. In addition, chRCC has to activate mutations in phosphatase and tensin
homolog (PTEN)-phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt)/mammalian target of the
rapamycin (mTOR) pathway [13], which would result in an appropriate target for an mTOR inhibitor.
Genomic instability, including whole-chromosome aneuploidy, is a hallmark of human cancer, but the
level of chromosomal losses in chRCC is unique. We have recently identified SF3B1 on chromosome
2 as a Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS (CYCLOPS) gene
with a highly significant positive correlation to hypoxia-inducible factor-1α (HIF1α) [26]. It is therefore
tempting to speculate that an Splicing factor 3B subunit 1 (SF3B1)/HIF1α pathway with potential
therapeutical relevance exists in chRCC.
Due to the unique genomic background, chRCC should be enrolled in separate clinical trials
to measure outcomes. However, chRCC is mostly included in clinical trials together with other
non-clear cell RCCs. Accurate classification of metastatic lesions is therefore important as chRCC
should be managed with different treatment algorithms. Kouba et al. have recently demonstrated
that cytogenetics, showing multiple genetic losses is an additional tool in a metastatic RCC lesion
for differential diagnosis of the primary [27]. Our own data show that chRCC without chromosomal
losses have an indolent behavior. Therefore, analysis of chromosomal losses by fluorescence in
situ hybridization (FISH) or other technologies could be used to assess the behavior of chRCC in
organ-confined tumors or to better characterize metastatic lesions of RCC.
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4. Materials and Methods
4.1. Swiss Patients
chRCC patients were identified from the files of the Department of Pathology and Molecular
Pathology of the University Hospital Zurich between 1993 and 2013. Our retrospective study fulfilled
the legal conditions according to Article 34 of the Swiss Law “Humanforschungsgesetz (HFG)”, which,
in exceptional cases, allows the use of biomaterial and patient data for research purposes without
informed consent, if i) it is impossible or disproportionately difficult to obtain patient consent; ii) there is
no documented refusal; iii) research interests prevail the individual interest of a patient. Law abidance
of this study was reviewed and approved by the ethics commission of the Canton Zurich (KEK-ZH-Nr.
2014-0604 on 1st April 2015; PB_2016-00811 on 22nd February 2016). This study was conducted in
accordance with the Declaration of Helsinki. The demographic and clinicopathological characteristics
for 42 chRCCs with clinical data are summarized in Table 1.
All tumors were reviewed by two pathologists (R.O. and H.M.). At least two sections were
observed for determination of the existence of pale cells in tumor tissue according to the standard
international protocol for pathological examination of RCCs [28,29]. ChRCCs were defined according
to the 2016 WHO classification as tumors composed of large polygonal cells with reticular, clear or
eosinophilic cytoplasm showing distinct cell borders, sometimes perinuclear halo and irregular
(raisinoid) nuclei.
Pale cells were described as being larger than eosinophilic cells, with voluminous pale,
finely reticular, but not clear cytoplasm and with distinct cell borders. We used hematoxylin and
eosin-stained sections and paid particular attention to the periphery of tumor cell sheet or nest, i.e.,
around the vascular septa and fibrous stroma in the tumor.
4.2. The Cancer Genome Atlas (TCGA) Dataset
Clinical information of TCGA-KICH was obtained from the National Cancer Institute Genomic
Data Commons Data Portal [30]. In TCGA-KICH dataset, there were 66 primary chRCCs with
matched copy number variation data [13]. The demographic and clinical characteristics for the selected
66 patients are summarized in Table 1. Detailed clinical data can be found in Table S2. For survival
analysis, the patients with missing or with too short a follow-up (i.e., less than 30 days) were excluded
from this study.
Digital whole slide images of TCGA cases were reviewed by using the Cancer Digital Slide
Archive [21]. Publically available Level 3 TCGA data were downloaded from the FIREHOSE
database [31], including GISTIC CN data.
4.3. Japanese Patients
chRCCs with available histological material was retrieved from the archives of 13 of the authors’
institutions. The institutions are: Niigata University Medical & Dental Hospital (cases from 2002
to 2015), Kansai Medical University Hirakata Hospital (cases from 2007 to 2015), Seirei Hamamatsu
General Hospital (cases from 2004 to 2015), Niigata Cancer Center Hospital (cases from 2002 to 2015),
Tachikawa General Hospital (cases from 2007 to 2015), Gifu University Hospital (cases from 2005 to
2015), Niigata City General Hospital (cases from 2007 to 2015), Nagaoka Red Cross Hospital (cases from
2008 to 2015), Tohoku University Hospital (cases from 2008 to 2015), Nagasaki University Hospital
(cases from 2014 to 2015), Iwate Medical University Hospital (cases from 2007 to 2015), Kochi Red Cross
Hospital (cases from 2007 to 2015), and Aichi Medical University Hospital (cases from 2008 to 2015).
The study did not include consultation cases. The study protocol was approved by the institutional
review boards in all participating institutions. This study was a retrospective observational study,
and an opt-out approach was used with the disclosure of this study on the website of each institution.
The patients with missing or too short a follow-up (i.e., less than 30 days) were excluded from this
Cancers 2019, 11, 1492 11 of 14
study. All chRCCs were negative for vimentin except for focal sarcomatoid areas. The demographic
and clinicopathological characteristics for the 119 chRCCs are summarized in Table 1.
4.4. OncoScan® CNV Assay of chRCCs
Tumor areas displaying >80% cancer cells without hemorrhage or necrosis were marked on the
hematoxylin and eosin slides. DNA from FFPE tumor tissue samples was obtained by punching 4
to 6 tissue cylinders (diameter 0.6 mm) from each sample. DNA extraction from FFPE tissue was
done as described [32]. The double-strand DNA concentration (dsDNA) was determined using
the fluorescence-based Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA).
Tumors with poor DNA quality were excluded from the study. Genome-wide DNA copy-number
alterations and allelic imbalances of 33 chRCC were determined using the Affymetrix OncoScan®
CNV Assay (Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA) as previously described [33].
The demographic and clinicopathological characteristics for 33 Swiss chRCCs with clinical data are
summarized in Table 1. Samples were further processed by IMGM Laboratories GmbH (Martinsried,
Germany) for CNV (copy number variation) determination according to the Affymetrix OncoScan CNV
Assay recommended protocol. The data were analyzed by the Nexus Copy Number 10.0 (Biodiscovery,
Inc., El Segundo, CA, USA) software using Affymetrix TuScan algorithm. All array data were also
manually reviewed for subtle alterations not automatically called by the software.
4.5. Statistical Analysis
All statistical analysis was done using R version 3.4.1 (R Foundation for Statistical Computing,
Vienna, Austria) and EZR, Version 1.37 (Saitama Medical Center, Jichi Medical University, Saitama,
Japan), which is a graphical user interface for R [34]. Fisher’s exact test was used to assess the
association between two categorical variables. A Kaplan–Meier analysis and the log-rank test were
used to derive and compare survival curves. Univariate and multivariate regression analyses with the
Cox proportional hazards model were used to identify prognostic factors. The significance threshold
was set at a p-value of 0.05.
5. Conclusions
In conclusion, the molecular difference between classic and eosinophilic chRCCs justifies the
definition of 2 chRCC variants. Using the absence of pale cells as a diagnostic criterion for the
eosinophilic variant may improve the reproducibility of histopathological subtyping.
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